Clinique du motoneurone

University Hospital Gui de Chauliac

The Montpellier ALS center is the referral center for the French region Occitania, a 5.8 Million people area

Clinique du motoneurone_logopng
University Hospital Gui de Chauliac

The Montpellier ALS center is included in the Department of Neurology of the University Hospital Gui de Chauliac, and is headed by Prof. Dr. William Camu. Established in 1988, the center obtained the national label of ALS center by the Ministry of Health in 2003. On a regular basis, between 500 and 600 patients with motor neuron diseases are in care. Research aspects of the center include epidemiology, phenotype, genetics, biomarkers and clinical trials. The center has participated in all the major trials in ALS since 1989, and conducted a series of pilot trials in ALS. Through national and international collaborations, more than 200 papers have been published by the center in referenced journals.

Contact
Location
Clinique du motoneurone, CHU Gui de Chauliac, 34295, Montpellier Cedex 5, France

Our specialists

William Camu

Professor of Neurology

Dr William Camu graduated as an MD and specialist in Neurology in […]

William Camu
Trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more